Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica

Fumitaka Shimizu, Kristin L. Schaller, Gregory P. Owens, Anne C. Cotleur, Debra Kellner, Yukio Takeshita, Birgit Obermeier, Thomas J. Kryzer, Yasuteru Sano, Takashi Kanda, Vanda A Lennon, Richard M. Ransohoff, Jeffrey L. Bennett

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Neuromyelitis optica (NMO) is an inflammatory disorder mediated by antibodies to aquaporin-4 (AQP4) with prominent blood-brain barrier (BBB) breakdown in the acute phase of the disease. Anti-AQP4 antibodies are produced mainly in the periphery, yet they target the astrocyte perivascular end feet behind the BBB. We reasoned that an endothelial cell-targeted autoantibody might promote BBB transit of AQP4 antibodies and facilitate NMO attacks. Using monoclonal recombinant antibodies (rAbs) frompatients with NMO, we identified two that strongly bound to the brain microvascular endothelial cells (BMECs). Exposure of BMECs to these rAbs resulted in nuclear translocation of nuclear factor κB p65, decreased claudin-5 protein expression, and enhanced transit of macromolecules. Unbiased membrane proteomics identified glucose-regulated protein 78 (GRP78) as the rAb target. Using immobilized GRP78 to deplete GRP78 antibodies from pooled total immunoglobulin G (IgG) of 50 NMO patients (NMO-IgG) reduced the biological effect ofNMO-IgG onBMECs. GRP78 was expressed on the surface ofmurineBMECs in vivo, and repeated administration of a GRP78-specific rAb caused extravasation of serum albumin, IgG, and fibrinogen into mouse brains. Our results identify GRP78 antibodies as a potential component ofNMO pathogenesis and GRP78 as a candidate target for promoting central nervous system transit of therapeutic antibodies.

Original languageEnglish (US)
Article numberaai9111
JournalScience Translational Medicine
Volume9
Issue number397
DOIs
StatePublished - Jul 5 2017

Fingerprint

Neuromyelitis Optica
Blood-Brain Barrier
Autoantibodies
Aquaporin 4
Antibodies
Immunoglobulin G
Endothelial Cells
Brain
Claudin-5
Claudins
Acute Disease
glucose-regulated proteins
Serum Albumin
Astrocytes
Proteomics
Fibrinogen
Central Nervous System
Monoclonal Antibodies
Membranes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shimizu, F., Schaller, K. L., Owens, G. P., Cotleur, A. C., Kellner, D., Takeshita, Y., ... Bennett, J. L. (2017). Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Science Translational Medicine, 9(397), [aai9111]. https://doi.org/10.1126/scitranslmed.aai9111

Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. / Shimizu, Fumitaka; Schaller, Kristin L.; Owens, Gregory P.; Cotleur, Anne C.; Kellner, Debra; Takeshita, Yukio; Obermeier, Birgit; Kryzer, Thomas J.; Sano, Yasuteru; Kanda, Takashi; Lennon, Vanda A; Ransohoff, Richard M.; Bennett, Jeffrey L.

In: Science Translational Medicine, Vol. 9, No. 397, aai9111, 05.07.2017.

Research output: Contribution to journalArticle

Shimizu, F, Schaller, KL, Owens, GP, Cotleur, AC, Kellner, D, Takeshita, Y, Obermeier, B, Kryzer, TJ, Sano, Y, Kanda, T, Lennon, VA, Ransohoff, RM & Bennett, JL 2017, 'Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica', Science Translational Medicine, vol. 9, no. 397, aai9111. https://doi.org/10.1126/scitranslmed.aai9111
Shimizu, Fumitaka ; Schaller, Kristin L. ; Owens, Gregory P. ; Cotleur, Anne C. ; Kellner, Debra ; Takeshita, Yukio ; Obermeier, Birgit ; Kryzer, Thomas J. ; Sano, Yasuteru ; Kanda, Takashi ; Lennon, Vanda A ; Ransohoff, Richard M. ; Bennett, Jeffrey L. / Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. In: Science Translational Medicine. 2017 ; Vol. 9, No. 397.
@article{6334521948194bf694e08c3feee49a87,
title = "Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica",
abstract = "Neuromyelitis optica (NMO) is an inflammatory disorder mediated by antibodies to aquaporin-4 (AQP4) with prominent blood-brain barrier (BBB) breakdown in the acute phase of the disease. Anti-AQP4 antibodies are produced mainly in the periphery, yet they target the astrocyte perivascular end feet behind the BBB. We reasoned that an endothelial cell-targeted autoantibody might promote BBB transit of AQP4 antibodies and facilitate NMO attacks. Using monoclonal recombinant antibodies (rAbs) frompatients with NMO, we identified two that strongly bound to the brain microvascular endothelial cells (BMECs). Exposure of BMECs to these rAbs resulted in nuclear translocation of nuclear factor κB p65, decreased claudin-5 protein expression, and enhanced transit of macromolecules. Unbiased membrane proteomics identified glucose-regulated protein 78 (GRP78) as the rAb target. Using immobilized GRP78 to deplete GRP78 antibodies from pooled total immunoglobulin G (IgG) of 50 NMO patients (NMO-IgG) reduced the biological effect ofNMO-IgG onBMECs. GRP78 was expressed on the surface ofmurineBMECs in vivo, and repeated administration of a GRP78-specific rAb caused extravasation of serum albumin, IgG, and fibrinogen into mouse brains. Our results identify GRP78 antibodies as a potential component ofNMO pathogenesis and GRP78 as a candidate target for promoting central nervous system transit of therapeutic antibodies.",
author = "Fumitaka Shimizu and Schaller, {Kristin L.} and Owens, {Gregory P.} and Cotleur, {Anne C.} and Debra Kellner and Yukio Takeshita and Birgit Obermeier and Kryzer, {Thomas J.} and Yasuteru Sano and Takashi Kanda and Lennon, {Vanda A} and Ransohoff, {Richard M.} and Bennett, {Jeffrey L.}",
year = "2017",
month = "7",
day = "5",
doi = "10.1126/scitranslmed.aai9111",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "397",

}

TY - JOUR

T1 - Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica

AU - Shimizu, Fumitaka

AU - Schaller, Kristin L.

AU - Owens, Gregory P.

AU - Cotleur, Anne C.

AU - Kellner, Debra

AU - Takeshita, Yukio

AU - Obermeier, Birgit

AU - Kryzer, Thomas J.

AU - Sano, Yasuteru

AU - Kanda, Takashi

AU - Lennon, Vanda A

AU - Ransohoff, Richard M.

AU - Bennett, Jeffrey L.

PY - 2017/7/5

Y1 - 2017/7/5

N2 - Neuromyelitis optica (NMO) is an inflammatory disorder mediated by antibodies to aquaporin-4 (AQP4) with prominent blood-brain barrier (BBB) breakdown in the acute phase of the disease. Anti-AQP4 antibodies are produced mainly in the periphery, yet they target the astrocyte perivascular end feet behind the BBB. We reasoned that an endothelial cell-targeted autoantibody might promote BBB transit of AQP4 antibodies and facilitate NMO attacks. Using monoclonal recombinant antibodies (rAbs) frompatients with NMO, we identified two that strongly bound to the brain microvascular endothelial cells (BMECs). Exposure of BMECs to these rAbs resulted in nuclear translocation of nuclear factor κB p65, decreased claudin-5 protein expression, and enhanced transit of macromolecules. Unbiased membrane proteomics identified glucose-regulated protein 78 (GRP78) as the rAb target. Using immobilized GRP78 to deplete GRP78 antibodies from pooled total immunoglobulin G (IgG) of 50 NMO patients (NMO-IgG) reduced the biological effect ofNMO-IgG onBMECs. GRP78 was expressed on the surface ofmurineBMECs in vivo, and repeated administration of a GRP78-specific rAb caused extravasation of serum albumin, IgG, and fibrinogen into mouse brains. Our results identify GRP78 antibodies as a potential component ofNMO pathogenesis and GRP78 as a candidate target for promoting central nervous system transit of therapeutic antibodies.

AB - Neuromyelitis optica (NMO) is an inflammatory disorder mediated by antibodies to aquaporin-4 (AQP4) with prominent blood-brain barrier (BBB) breakdown in the acute phase of the disease. Anti-AQP4 antibodies are produced mainly in the periphery, yet they target the astrocyte perivascular end feet behind the BBB. We reasoned that an endothelial cell-targeted autoantibody might promote BBB transit of AQP4 antibodies and facilitate NMO attacks. Using monoclonal recombinant antibodies (rAbs) frompatients with NMO, we identified two that strongly bound to the brain microvascular endothelial cells (BMECs). Exposure of BMECs to these rAbs resulted in nuclear translocation of nuclear factor κB p65, decreased claudin-5 protein expression, and enhanced transit of macromolecules. Unbiased membrane proteomics identified glucose-regulated protein 78 (GRP78) as the rAb target. Using immobilized GRP78 to deplete GRP78 antibodies from pooled total immunoglobulin G (IgG) of 50 NMO patients (NMO-IgG) reduced the biological effect ofNMO-IgG onBMECs. GRP78 was expressed on the surface ofmurineBMECs in vivo, and repeated administration of a GRP78-specific rAb caused extravasation of serum albumin, IgG, and fibrinogen into mouse brains. Our results identify GRP78 antibodies as a potential component ofNMO pathogenesis and GRP78 as a candidate target for promoting central nervous system transit of therapeutic antibodies.

UR - http://www.scopus.com/inward/record.url?scp=85021950257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021950257&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aai9111

DO - 10.1126/scitranslmed.aai9111

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 397

M1 - aai9111

ER -